BioMimetic Therapeutics, Inc. (NASDAQ:BMTI.DL)

CAPS Rating: No stars

The Company develops and commercializes bio-active drug-device combination products for the healing of musculoskeletal injuries and diseases, including periodontal, orthopedic, spine and sports injury applications.

Recs

1
Player Avatar forbes10 (99.87) Submitted: 6/25/2009 9:09:58 AM : Outperform Start Price: $9.87 BMTI.DL Score: -70.91

disruptive technology will turbocharge this stock

Featured Broker Partners


Advertisement